Highlights
think traditionally we have practiced this paradigm that really hinges on how long patients have been in remission based on their last round of platinum-based therapy, but I think we are now moving more to molecular testing for current treatment, as opposed to this arbitrary time of platinum-free interval. So, for example if the tumor testing shows that the patient has a mutation, that will be amenable to immunooncology, let us say they have PD-L1 overexpression, they may become eligible for something like pembrolizumab as opposed to more platinum.
So, I think we are not there yet, but we are beginning to see a shift away from just the platinum-free interval as being the deciding feature that makes us choose the next line of therapy. So, I can tell you that our cancer practice, the whole cancer center in my hospital has moved to biosimilars, and I think it was a decision made at the hospital level just based on pricing. So, I see no pharmacology drugs in the ambulatory center, and specifically oncology drugs are driving a lot of the medical cost of care, so our cancer center made the decision that across all disease types, not just gyne, but any other cancer where the [bevacizumab] biosimilar agent is now available, that we would make the switch.
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.